دورية أكاديمية
Commercial Bone Grafts Claimed as an Alternative to Autografts: Current Trends for Clinical Applications in Orthopaedics
| العنوان: | Commercial Bone Grafts Claimed as an Alternative to Autografts: Current Trends for Clinical Applications in Orthopaedics |
|---|---|
| المؤلفون: | Marco Govoni, Leonardo Vivarelli, Alessandro Mazzotta, Cesare Stagni, Alessandra Maso, Dante Dallari |
| المصدر: | Materials, Vol 14, Iss 12, p 3290 (2021) |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Technology LCC:Electrical engineering. Electronics. Nuclear engineering LCC:Engineering (General). Civil engineering (General) LCC:Microscopy LCC:Descriptive and experimental mechanics |
| مصطلحات موضوعية: | autograft alternatives, commercial bone allografts, cellular bone matrices, growth factors, bioactive peptides, xeno-hybrid bone grafts, Technology, Electrical engineering. Electronics. Nuclear engineering, TK1-9971, Engineering (General). Civil engineering (General), TA1-2040, Microscopy, QH201-278.5, Descriptive and experimental mechanics, QC120-168.85 |
| الوصف: | In the last twenty years, due to an increasing medical and market demand for orthopaedic implants, several grafting options have been developed. However, when alternative bone augmentation materials mimicking autografts are searched on the market, commercially available products may be grouped into three main categories: cellular bone matrices, growth factor enhanced bone grafts, and peptide enhanced xeno-hybrid bone grafts. Firstly, to obtain data for this review, the search engines Google and Bing were employed to acquire information from reports or website portfolios of important competitors in the global bone graft market. Secondly, bibliographic databases such as Medline/PubMed, Web of Science, and Scopus were also employed to analyse data from preclinical/clinical studies performed to evaluate the safety and efficacy of each product released on the market. Here, we discuss several products in terms of osteogenic/osteoinductive/osteoconductive properties, safety, efficacy, and side effects, as well as regulatory issues and costs. Although both positive and negative results were reported in clinical applications for each class of products, to date, peptide enhanced xeno-hybrid bone grafts may represent the best choice in terms of risk/benefit ratio. Nevertheless, more prospective and controlled studies are needed before approval for routine clinical use. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 14123290 1996-1944 74210424 |
| Relation: | https://www.mdpi.com/1996-1944/14/12/3290; https://doaj.org/toc/1996-1944 |
| DOI: | 10.3390/ma14123290 |
| URL الوصول: | https://doaj.org/article/bcc223a742104247b604ebe4560a5157 |
| رقم الأكسشن: | edsdoj.bcc223a742104247b604ebe4560a5157 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14123290 19961944 74210424 |
|---|---|
| DOI: | 10.3390/ma14123290 |